Zhuhai Hairuide Bioscience and Technology Co., Ltd., was established in February 2009 with a registered capital of 20 million RMB, which is located in the medical base of Jinwan District, Zhuhai. Our company is an integrated firm includes the research, production and sales of pharmaceutical raw materials with its’ intermediate,with 6 registered intellectual property rights.
The production area covers about 6000 square meters. We are good at the Grignard reaction, ultra-low temperature reaction (-80℃), anhydrous and oxygen-free reaction, core technology development and its optimization, having the ability with completed facility for the pilot and commercial production.
Our main business is the research, production and sales of the APIs and its’ intermediates,which covers the fields of antiviral, anticoagulant, antidepressant, antiepileptic, gastrointestinal disease, diabetes and antiallergic ect. Such as Oseltamivir Phosphate and its intermediates, Edoxaban and its intermediates, Vonourazan Fumarate and its intermediates, Tedizolid Phosphate and its intermediates, Dapagliflozin and Canagliflozin and their intermediates, Fluvoxamine Maleate and its intermediates, Zonisamide and its intermediates, Fimasartan and its intermediates, ilaprazole and its intermediates, Carbinoxamine Maleate Salt and its intermediates etc.
Our company has achieved the ISO9001 quality management system certificate and passed many on-site audits by domestic and international customer, and the products are exported to Southeast Asia,Korea,Japan, Middle East and South America.
In 2019, our company invested 250 million RMB for construction an new GMP factory located at Gaolan Port National Chemical Park in Jinwan District. The first phase of the factory has built 6 high-standard multi-layer API workshops covers an area of 42 acres,and its capacity is 300 tons/year. The new plant is designed and constructed in strict accordance with CGMP standards, will build its’ quality system that meets ICH, EU and US FDA standards. It is expected to be launched for production in mid-2022.
Our company adheres to the goal of "Development and Production of cutting-edge APIs and intermediates" as enterprise development, adheres to the tenet of "Pursuing the qualify and affordable product, and creating the greatest value and health for patients". We constantly improves our management system and optimize the production process to create the high quality,affordable and safe medicine for the world.
Process Capability : Our company has standardized production base and high-quality professional production wit high-end R & D personnel and stable process.
After-sale Service : Our company has special after-sales staff to provide our best service.
China (Mainland)
